title: [A case of advanced gastric cancer producing alpha fetoprotein with multiple liver metastases responding to TS-1 after TAE].
abstract: We report a case of advanced gastric cancer producing Alpha Fetoprotein (AFP) with multiple liver metastases in which TS-1 is effective. Prognosis of gastric cancer producing AFP is well known to poor. A 74-year-old female was admitted complaining of anemia. She was diagnosed as having advanced gastric cancer with multiple liver metastases producing AFP by endoscopy, computed tomography and angiography. Her serum AFP level was 17,666 ng/ml and her serum CEA level was 5-2 ng/ml. After transarterial embolization (TAE), her family rejected her operation because it would not be curative. So, she was treated with TS-1, 40 mg, administered orally every day, followed by 14 days rest, as the first course. The next was TS-1, 80 mg orally administered for 6 courses. Her serum AFP level was down from 17,666 ng/ml to 94 ng/ml after 6 courses of TS-1. CT revealed that liver metastases did not change and endoscopy showed the primary lesion has diminished. Our report is the first to demonstrate that TS-1 is effective for patients with advanced gastric cancer producing AFP with multiple liver metastases.
authors.affiliation: Dept. of Surgery, Kobe Ekisaikai Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Okazaki
authors.forename: J
authors.initials: J
authors.lastname: Yamamura
authors.forename: Y
authors.initials: Y
authors.lastname: Kawasaki
authors.forename: M
authors.initials: M
authors.lastname: Ohtsuru
authors.forename: K
authors.initials: K
authors.lastname: Kobayakawa
authors.forename: S
authors.initials: S
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Oka
authors.forename: M
authors.initials: M
authors.lastname: Yamamura
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D010094:Oxonic Acid / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005641:Tegafur / Q000627:therapeutic use*; D000509:alpha-Fetoproteins / Q000096:biosynthesis*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; D000509:alpha-Fetoproteins; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid